BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cubicin daptomycin regulatory update

Cubist submitted a Citizen's Petition to FDA asking the agency to not approve ANDAs for generic versions of the company's antibiotic Cubicin daptomycin. The petition, filed Dec. 3, asks FDA to require applicants to demonstrate comparability to Cubicin using microbiological...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >